Biomedical subjects

B Lomanto

Publications and source records attributed to B Lomanto.

At least 19 recordsLinked to original sources

PubMed1989

Mexiletine for the treatment of ventricular arrhythmias associated with chronic obstructive pulmonary disease.

Ventricular arrhythmias complicating chronic obstructive pulmonary disease, when refractory to the correction of acidosis and hypoxia, may lead to a poor prognosis. Mexiletine efficacy was assessed in 14 patients (pts.) with chronic obstructive pulmonary disease and premature ventricular contractions; they entered a cross-over trial consisting of 7-day therapy with oral placebo and mexiletine (200 mg q.i.d.). The hourly means of premature ventricular contractions, their hourly peaks and the severity scores of arrhythmias were compared. The analysis of linear regression showed a slight spontaneous variability of premature ventricular contractions in the study group. Unexpectedly, the highly homogeneous data raised the question if this method of evaluation for anti-arrhythmic therapy reaches a satisfactory conclusion. Nevertheless, treatment with mexiletine significantly reduced the premature ventricular contractions count and their hourly peak (p less than 0.001) as well as their severity score (p less than 0.001). Analysis of linear regression and confidence intervals confirmed the efficacy of the drug. According to the statistical method used, antiarrhythmic therapy with mexiletine generally achieved its purpose in pts. with chronic obstructive pulmonary disease.

Aged↗

PubMed1988

[Enalapril and acebutolol in essential arterial hypertension. Comparison of the 2 drugs and evaluation of their combination].

The effects of a mid-term antihypertensive treatment with Acebutolol (A) 400 mg once-daily alone, Enalapril (E) 20 mg once-daily alone and their combination (A + E) in 12 hypertensive patients (pts.) have been evaluated. The diastolic (DBP) and systolic (SBP) blood pressure values have been evaluated in supine and upright position and at the end of an exercise test. Basic values obtained after 3 weeks of treatment with placebo have been matched with values observed after 3 months of each treatment (A; A + E; E). In order to evaluate the effectiveness of the combination, pts. were divided into two groups: the first group was given A, than A + E and finally E; in the second group the order was reversed. Our findings showed a more significant reduction of DBP in supine and upright position and after exercise (p less than .05) and of SBP in supine and upright position (p less than .05) after treatment with E. The addition of A to E did not produce a further significant reduction in blood pressure values except after exercise (p less than .01).

Acebutolol↗

PubMed1986

Multicenter study on the clinical efficacy of chronic ibopamine administration.

The purpose of this multicenter study was to evaluate the therapeutic efficacy of ibopamine (SB-7505), the 3,4-diisobutyrylester of N-methyldopamine, chronically administered to patients with severe congestive heart failure (CHF) in whom traditional therapy had been ineffective. 55 patients chronically treated with cardiac glycosides and diuretics were assigned to an investigation covering three stages each lasting 7 days. Stage A: continuation of traditional therapy (glycosides and diuretics). Stage B: addition of ibopamine to the glycoside/diuretic therapy. Stage C: withdrawal of ibopamine. Heart rate, blood pressure, body weight, diuresis and 8 target symptoms of CHF (clinical scores) and hematochemical parameters were recorded throughout the three stages. The addition of ibopamine to traditional therapy led to a significant improvement. By contrast, after ibopamine had been withdrawn patients worsened. No hematochemical parameters were modified during the trial. None of the patients experienced any significant side-effects.

Aged↗

PubMed1979

[Systolic time intervals in essential hypertension. I. Study of untreated patients].

15 patients with Stage II (VHO Classification) hypertension were studied before treatment. The following systolic time intervals were measured: 1) total electromechanical systolic period (QS2); 2) left ventricular ejection time (LVET); 3) interval between the first and second sounds (S1 S2); 4) pre-ejection period (PEP); 5) interval between the start of QRS and the first sound (QS1); 6) isovolumetric contraction time (ICT); 7) PEP/LVET ratio. The values measured were compared to the theoretical values obtained by the Weissler regression methods, taking into consideration the sex of the patient and the heart rate. QS1 and the ICT were both a slightly longer than normal; the PEP was increased by 25.6% (26.8 ms), whilst the LVET was decreased by 7.9% (24.0 ms), both differences being significant; QS2 increased by 1.1% (to 4.9 ms) but this was not significant; the PEP/LVET ratio was 0.479 +/- 0.12. These results seem to characterise moderate systemic hypertension with a significant relation between the variations of PEP, LVET and PEP/LVET with the diastolic blood pressure; although they have no absolute value, these results may be used in a longitudinal study to follow the course of hypertension and to study the effects of treatment.

Adult↗

PubMed1979

[Systolic time intervals in essential hypertension. II. Variations produced by treatment with labetalol].

Characteristic changes in the systolic time intervals in Stage II (WHO Classification) hypertension have been demonstrated comprising an increase in the pre ejection period (PEP), a decrease in the left ventricular ejection time (LVET) both statistically significant, and an increase in the PEP/LVET ratio. We have studied the variations brought about by effective hypotensive therapy with an alpha and beta blocking agent (Labetalol) in 15 patients over a period of 90 days, with an average dosage of 420 mg/day in three divided doses. There was no significant variations in the PEP, but the LVET which had been reduced by 7.9% returned to within 2.8% of normal, with a reduction in the PEP/LVET ratio. The variations of these systolic indices (generally considered to be the most sensitive assessment of left ventricular function) seem to show that the hypotensive effect of labetalol is not related to a reduction in cardiac efficiency.

Adult↗

PubMed1977

[Clinical aspects of myocardial infarction in elderly people. Statistical study of 203 cases (author's transl)].

A statistical study was done on two groups of patients. The first group included 128 subjects of less than 65 years of age. The second group comprised 75 subjects aged 65 years or older. The purpose of the study was to identify the most relevant clinical aspects of myocardial infarction in older aged patients. The following variables were taken into consideration: sexual distribution, predisposing factors, causative factors, initial symptoms, site of infarction, physical and instrumental indications, cardiac and extracardiac complications, immobilization time, recovery time, residual aspects at patient discharge, mortality and tyme and type of death. The analysis was performed using both non parametric X2 test and correlating some variables with age independently of the subdivision of cases in groups, according to the method of multiple step-wise and simple regression. In the older age group the most significant statistical data was: the major incidence of infarcts was in women; the prevalence of predisposing factors such as hypertension and diabetes; the most frequent presentation of initial atypical symptoms; the most elevated incidence of hemodynamic complications and the highest mortality.

Age Factors↗

PubMed1976